Status:
COMPLETED
Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study
Lead Sponsor:
Ipsen
Conditions:
Precocious Puberty
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
The purpose of the protocol is to assess the efficacy of triptorelin 11.25 mg with respect to the proportion of children who maintain a regression or stabilisation of sexual maturity until the end of ...
Eligibility Criteria
Inclusion
- The child must have completed study 2-54-52014-143
- The child must have an effective response to 2 injections of triptorelin 11.25 mg according to investigator's evaluation with no significant treatment side effects
Exclusion
- The patient has a known hypersensitivity to any of the test materials or related compounds
- The patient is unable or unwilling to comply fully with the protocol
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00909844
Start Date
April 1 2008
End Date
January 1 2016
Last Update
January 15 2019
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Hôtel Dieu (CHU)
Angers, France, 49033
2
Medical Centre
Bordeaux, France, 33000
3
Hôpital Flaubert
Le Havre, France, 76083
4
Hôpital Archet II
Nice, France, 06202